Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — H1 2021 Earnings Presentation
14 slides from Trendlines's earnings presentation, August 2021
Slide 1: The Trendlines Group: Healthcare and Food: Investing for change
The Trendlines Group Healthcare and Food: Investing for change Steve Rhodes Todd Dollinger Haim Brosh Chair and CEO Chair and CEO Chief Financial Officer August 2021 SGX:42T OTCQX: TRNLY
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Agenda
Agenda • Corporate highlights • Portfolio at a glance • Financial highlights • Sustainability commitment • Sum-up and Q&A 3
Slide 4: January – August 2021 developments
January – August 2021 developments Execution of non-binding letter of intent The Company did not proceed with the proposed dual primary listing and LOI (LOI) for acquisition of portfolio company IPO securities offer on the Tel Aviv Stock by a public corporation Exchange. Regulatory clearance FDA for
Slide 5: 23 agrifood portfolio companies
4 agrifood frontrunners Artificial intelligence analytics employing drones for user-generated data acquisition First commercial grasshopper farm in the world for field crop management • Joint development with a large food • Strategic service agreement company • Collaboration with strategic partners
Slide 6: 35 healthcare portfolio companies
6 leading healthcare Meniscus repair system • FDA and CE clearance • Launched commercial sales in U.S. Removable stent following sinus surgery • Began sales in US • FDA clearance companies Drug/device combination for the treatment of Digital home dialysis bladder diseases • FDA clearance in process
Slide 7: Portfolio value expansion – 10% growth in H1 2021
Portfolio value expansion – 10% growth in H1 2021 US$ millions 140 120 Portfolio value (excluding 13 Singapore consolidated portfolio companies) 100 Cumulative exit proceeds 80 60 40 20 0 31.12.08 31.12.09 31.12.10 31.12.11 31.12.12 31.12.13 31.12.14 31.12.15 31.12.16 31.12.17 31.12.18 31.12.19 31.1
Slide 8: Key financial developments
Key financial developments 30 June 2021 31 December 2020 Portfolio value US$92.1 million US$83.7 million Book value US$100.5 million US$96.3 million NAV per share US$0.13; S$0.17 US$0.12; S$0.16 H1 2021 H1 2020 Net gain/(loss) US$4.1 million (US$4.1 million) 8
Slide 9: Balance sheet: 30 June 2021
Balance sheet: 30 June 2021 ASSETS US$'000 LIABILITIES US$'000 Current assets Current liabilities Cash and cash equivalents 6,664 Lease liability 669 Short-term bank deposits 4,268 Loan 3,005 Trade and other payables 2,165 Accounts and other receivables 2,738 Deferred revenues 220 Short-term loans t
Slide 10: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands Half year ended 30 June 2021 2020 Income Gain/Loss from change in fair value of investments in Portfolio 6,190 (3,626) Companies Income from services to Portfolio Companies 765 1,799 Income fr
Slide 11: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands Half year ended 30 June 2021 2020 Expenses Operating, general and administrative expenses 4,858 3,373 Marketing expenses 176 96 R&D expenses, net 704 493 Financial expenses 978 406 Total expen
Slide 12: An active commitment to sustainability
An active commitment to sustainability Sustainability assessment of our portfolio companies to define and accurately report the companies that can cut carbon emissions, leveraging their social and economic worth as commercial entities, and increasing their overall value. 12
Slide 13: We invest in food and healthcare innovation to impact lives
We invest in food and healthcare innovation to impact lives 58 portfolio companies 20 advanced-stage companies $307 million raised for portfolio companies 9 Exits 8.7X return and 175% IRR on exits 13
Slide 14: SGX: 42T OTCQX: TRNLY www.trendlines.com
SGX: 42T Steve Rhodes, Chair & CEO OTCQX: TRNLY steve@trendlines.com Todd Dollinger, Chair & CEO +972.72.260.7000 todd@trendlines.com www.trendlines.com Haim Brosh, Chief Financial Officer haim@trendlines.com August 2021